Brainstorm Cell Therapeutics | BCLI - Ebitda


Brainstorm Cell Therapeutics reported $-3.04M in EBITDA for its fiscal quarter ending in March of 2025.





Ebitda Change Date
Alterity Therapeutics Limited AUD -7.72M 2.99M Jun/2023
Biogen USD 573.2M 253.7M Dec/2025
Brainstorm Cell Therapeutics USD -3.04M 99K Mar/2025
Cipla INR 12.55B 6.4B Dec/2025
Clal Biotechnology ILS -5.3M 2.09M Dec/2022
Compugen USD -7.89M 536K Sep/2025
CSL USD 3.13B 1.17B Dec/2025
Cytokinetics USD -277.18M 169.36M Sep/2025
Gilead Sciences USD 4.03B 628M Sep/2025
Grifols EUR 482.04M 7.04M Sep/2025
Halozyme Therapeutics USD 21.9M 226.34M Dec/2025
Mesoblast USD -20.3M 2.51M Dec/2025